CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue	$ 5	$ 8
Operating expenses:
Research and development	1,062	1,617
General and administrative	6,245	6,401
Depreciation and amortization	84	55
Total operating expenses	7,391	8,073
Loss from operations	(7,386)	(8,065)
Other income (expense):
Interest income, net	4	0
Loss before income taxes	(7,382)	(8,065)
Income taxes (benefit)	0	0
Net loss	(7,382)	(8,065)
Non-controlling interest	50	102
Net loss attributable to BioSig Technologies, Inc.	(7,332)	(7,963)
Preferred stock dividend	(2)	(2)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (7,334)	$ (7,965)
Net loss per common share, basic and diluted (in Dollars per share)	$ (0.12)	$ (0.22)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	61,426,514	35,997,298
Service [Member]
Revenue	$ 5	$ 8